A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder Patients

NCT00368706 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

246

Enrollment

INDUSTRY

Sponsor class

Conditions

Urinary Bladder, Overactive

Interventions

DRUG: solifenacin succinate
DRUG: tolterodine

Sponsor

Astellas Pharma Inc